Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 8th Floor 36 Dame Street, Dublin, Ireland

CaptBeer Jul. 4 at 5:12 PM

https://www.linkedin.com/posts/shaun-khanna-7633a5ab_cardiology-preventivecardiology-lipidology-share-7478925941021274112-kDik/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAdDmycBzT_CwLIulyFqANe8SLMF4KH2Odo $AMRN

0 · Reply

CaptBeer Jul. 4 at 1:14 PM

$AMRN HAPPY BIRTHDAY AMERICA!

0 · Reply

EnVila Jul. 4 at 11:26 AM

$AMRN New phase III trial, ending 2030: "A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of DR10624 Added to Standard Icosapent Ethyl Therapy in Adults With Severe Hypertriglyceridemia" https://clinicaltrials.gov/study/NCT07680829

2 · Reply

CaptBeer Jul. 3 at 10:35 PM

BEER GOOD $AMRN GOOD!

0 · Reply

declanaidan Jul. 3 at 8:32 PM

$AMRN

1 · Reply

DoMoreCharity Jul. 3 at 1:23 PM

$AMRN European Medicines Agency versus Italian Medicines Agency indications for icosapent ethyl: a long and winding road https://www.sciencedirect.com/science/article/pii/S0939475326002826

1 · Reply

DoMoreCharity Jul. 3 at 4:37 AM

$AMRN https://youtu.be/lSop0XPeFo8?is=wR5oGXQNR4jHXZAV

0 · Reply

DoMoreCharity Jul. 2 at 10:34 PM

$AMRN https://x.com/amarincorp/status/2072704387894378677?s=46

0 · Reply

declanaidan Jul. 2 at 8:27 PM

$AMRN Last year, July 3, 2025, we closed at $16.37 🤔🥴 July 3, 2026 we sit at $16.37.

2 · Reply

MorrisBorris2Duex Jul. 2 at 7:30 PM

$AMRN 16.36 guess

0 · Reply

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

May 27, 2026, 8:00 AM EDT - 5 weeks ago

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

Apr 29, 2026, 7:00 AM EDT - 2 months ago

Amarin Reports 2026 First Quarter Financial Results

Apr 15, 2026, 8:00 AM EDT - 2 months ago

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

2026-03-18T12:41:54.000Z - 3 months ago

Amarin highlights new recommendation for treatment of CV risk

2026-03-16T12:27:24.000Z - 3 months ago

Amarin to present data in patients at extreme cardiovascular risk

2026-03-02T13:26:30.000Z - 4 months ago

Amarin highlights recent data published on REDUCE-IT study

2026-02-25T12:14:50.000Z - 4 months ago

Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities

2026-02-23T13:23:34.000Z - 4 months ago

Amarin issues call to action for American Heart Month

Feb 23, 2026, 8:00 AM EST - 4 months ago

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Jan 16, 2026, 2:44 PM EST - 6 months ago

US Supreme Court to hear 'skinny label' patent fight involving Amarin

2026-01-09T12:13:43.000Z - 6 months ago

Amarin comments on recent innovations for patients with elevated triglycerides

Jan 9, 2026, 7:00 AM EST - 6 months ago

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

2026-01-08T12:06:26.000Z - 6 months ago

Amarin expects Q4 net revenue $48M-$43M

2025-11-10T00:10:10.000Z - 8 months ago

Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

Nov 9, 2025, 4:15 PM EST - 8 months ago

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 3, 2025, 8:30 AM EST - 8 months ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

2025-10-29T11:11:18.000Z - 8 months ago

Amarin reports Q3 EPS (2c) vs (6c) last year

2025-10-27T12:05:31.000Z - 8 months ago

Amarin issues statement related to recent action by FDA for fenofibrate drugs

2025-10-14T12:10:55.000Z - 9 months ago

Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

2025-09-01T12:30:11.000Z - 10 months ago

Amarin presents new REDUCE-IT analyses

Aug 31, 2025, 8:30 AM EDT - 10 months ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 11 months ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

2025-08-25T12:05:06.000Z - 11 months ago

Amarin announces upcoming presentations at ESC Congress 2025

Aug 25, 2025, 8:00 AM EDT - 11 months ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

2025-07-30T11:11:52.000Z - 1 year ago

Amarin expects accelerated in-market demand in Europe

Jul 30, 2025, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 1 year ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

2025-06-24T11:05:33.000Z - 1 year ago

Amarin announces exclusive license, supply agreement with Recordati

Jun 24, 2025, 7:05 AM EDT - 1 year ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

2025-04-29T20:40:18.000Z - 1 year ago

Amarin regains compliance with Nasdaq

Apr 29, 2025, 4:15 PM EDT - 1 year ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 1 year ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 1 year ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 1 year ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 1 year ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 27, 2025, 9:00 AM EST - 1 year ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 2 years ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 2 years ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 2 years ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 2 years ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 2 years ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 2 years ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 2 years ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 2 years ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 2 years ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 7:00 AM EST - 2 years ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 8:00 AM EST - 2 years ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Jan 22, 2024, 7:30 AM EST - 2 years ago

Amarin Chairman & CEO Issue Letter to Shareholders

Jan 10, 2024, 7:00 AM EST - 2 years ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Dec 11, 2023, 8:00 AM EST - 2 years ago

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 4, 2023, 4:23 PM EST - 2 years ago

Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership

CaptBeer Jul. 4 at 5:12 PM

0 · Reply

CaptBeer Jul. 4 at 1:14 PM

$AMRN HAPPY BIRTHDAY AMERICA!

0 · Reply

EnVila Jul. 4 at 11:26 AM

2 · Reply

CaptBeer Jul. 3 at 10:35 PM

BEER GOOD $AMRN GOOD!

0 · Reply

declanaidan Jul. 3 at 8:32 PM

$AMRN

1 · Reply

DoMoreCharity Jul. 3 at 1:23 PM

$AMRN European Medicines Agency versus Italian Medicines Agency indications for icosapent ethyl: a long and winding road https://www.sciencedirect.com/science/article/pii/S0939475326002826

1 · Reply

DoMoreCharity Jul. 3 at 4:37 AM

$AMRN https://youtu.be/lSop0XPeFo8?is=wR5oGXQNR4jHXZAV

0 · Reply

DoMoreCharity Jul. 2 at 10:34 PM

$AMRN https://x.com/amarincorp/status/2072704387894378677?s=46

0 · Reply

declanaidan Jul. 2 at 8:27 PM

$AMRN Last year, July 3, 2025, we closed at $16.37 🤔🥴 July 3, 2026 we sit at $16.37.

2 · Reply

MorrisBorris2Duex Jul. 2 at 7:30 PM

$AMRN 16.36 guess

0 · Reply

NotAgain2024 Jul. 2 at 4:34 PM

$AMRN Imagine having AMRN on your resume hahaha, jebus, auto reject.

0 · Reply

PghKid1 Jul. 2 at 3:54 PM

$AMRN nothing but a prick tease!

0 · Reply

Biotechnicity Jul. 2 at 1:58 PM

$AMRN $CYTH $ZVRA I’m extremely close to closing my position here in $RFL Once the idiot longs return with their parked I.D.’s we know the hedge funds are locked and loaded to go short behind them because that’s where the money is — going short. P-3 data here is likely NOT STAT-SIG. However, as I’ve repeatedly suggested it DOESN’T HAVE TO BE. It’s not even the primary catalyst that has moved this share price sky high over the past month. I can support every facet of the above statement with TANGIBLE FACTS. Can you support the argument against that with something other than the “Beautiful Molecule” theory or the “they waited at 48-Weeks because the data was so good” nonsense/some sense theory? Please stop! Go back to sleep Cythians before the color we see today becomes the color we see everyday. I’m seeing red just responding to your passive rage.

0 · Reply

Md80dog Jul. 2 at 1:31 PM

$AMRN My biggest question if I were a buyer would be: Not “What is the 20-year model?” but rather: 1. Can LR-EtEPA obtain durable patent protection? 2. Can EMT2 generate compelling clinical evidence? 3. Can the core VASCEPA business stabilize or grow under the new commercial model? 4. What probability should be assigned to each of those outcomes? Those probabilities largely determine the valuation more than any single long-term spreadsheet. Overall, I’d rate the post as: * Facts: ~60% * Reasonable inference: ~25% * Speculation: ~15% The central idea—that sophisticated buyers value pharmaceutical companies using long-term discounted cash-flow models—is sound. The suggestion that Barclays is already showing buyers a specific 20-year UFCF curve for LR-EtEPA and EMT2 is plausible as a possibility, but there is no public evidence confirming that today.

2 · Reply

SanDiegoLiving Jul. 2 at 11:26 AM

$AMRN DENNER’S MEDCO PLAYBOOK: DIANE SULLIVAN, WHERE IS AMARIN’S 20-YEAR LR MODEL? 🚨 MedCo sold inclisiran to Novartis before FDA/EMA approval. What mattered was: 🧬 Issued patent protection 📊 Phase 3 conviction (Orion trials) 📈 A 20-year buyer model Its 14D-9 projected through 2040: 📈 Revenue: $0 → $6.49B peak 💰 UFCF: -$352M → $3.71B peak Amarin now sits in a similar value-window: ✅ Barclays engaged on strategic alternatives ✅ Recordati reset EU ✅ LR-EtEPA in the decisive patent window ✅ EMT2 Phase 3 near the point where oncology value can be modeled ✅ Cash/no debt gives buyers time to underwrite the curve This is where real buyer math begins. So the question for Diane Sullivan/Amarin management: 📌 What branded price can LR restore in the U.S.? 📌 Does EMT2 read out strong enough to support CRC revenue modeling globally? 📌 What 20-year UFCF curve is Barclays likely preparing to show buyers? The 20-year curve likely decides Amarin's final value 📈

0 · Reply

RallyReaper Jul. 2 at 11:24 AM

$AMRN had to check..

0 · Reply

BobGood Jul. 2 at 11:17 AM

$AMRN @declanaidan … I would say, Amarin management to get this ticket sold out ASAP instead of getting back into bio indexes … holding & waiting is soooo long with this stock. Hence don’t want to waste more time with management !!! GL

0 · Reply

declanaidan Jul. 1 at 8:43 PM

$AMRN Over the last month this has been under slow, steady, measured accumulation. The low float and fact most shares in hands of retail like us, dictates that as only option for bigger investors. Amarin management needs to get this ticker back in bio indexes.

1 · Reply

declanaidan Jul. 1 at 8:05 PM

$AMRN Decent start to second half of '26. Close near HOD on flat market day. In Spirit of '76, maybe we can break 17.76 in July🎇🎆

0 · Reply

CaptBeer Jul. 1 at 12:19 PM

$AMRN Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape https://www.amarincorp.com/news-and-media/amarin-reaffirms-proven-guideline-recommended-role-vascepar?_gl=1*1ntpbpp*_up*MQ..*_ga*MTI2NDc1NjAxMy4xNzgyOTA3Njk2*_ga_HEN7SS1YRY*czE3ODI5MDc2OTYkbzEkZzEkdDE3ODI5MDc2OTgkajU4JGwwJGg2MTcwMjg

1 · Reply

Freifaller Jul. 1 at 7:53 AM

$AMRN Anyone knows the status of EMT2 trial? Should be over....when can we hear anything from it?

1 · Reply

Md80dog Jul. 1 at 12:55 AM

$AMRN No. Based on the Form 4 you shared, CEO Aaron Berg did not make an open-market purchase. Here’s what happened: * 6,250 ADS were acquired (Code “A”) because previously granted Restricted Stock Units (RSUs) vested. This is compensation, not a purchase. * 3,197 ADS were withheld (Code “F”) at $16.35 to pay the taxes due on that vesting. The filing specifically states this is not a market sale. * After these transactions, he owned 88,845 ADS directly. For shareholders, this filing is generally viewed as neutral: * ✅ He did not buy shares with his own money. * ✅ He did not sell shares into the market. * ✅ It reflects routine compensation vesting and tax withholding.

1 · Reply

Market Cap	343.26M
Revenue (ttm)	213.65M
Net Income (ttm)	-38.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.16%
Debt to Equity Ratio	0.00

Volume	91,600
Avg Vol	85,808
Day's Range	N/A - N/A
Shares Out	20.97M
Stochastic %K	58%
Beta	0.80
Analysts	Hold
Price Target	$14.00